{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:24:27Z","timestamp":1794885867456,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004097","name":"ARC Foundation","doi-asserted-by":"crossref","award":["ARC-RAC16002KSA-R15093KS"],"award-info":[{"award-number":["ARC-RAC16002KSA-R15093KS"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0071"],"award-info":[{"award-number":["ANR-11-LABX-0071"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA8297\/1-1"],"award-info":[{"award-number":["HA8297\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Federal Institute of Technology Zurich"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adrenocortical carcinoma is rare and aggressive endocrine cancer of the adrenal gland. Within adrenocortical carcinoma, a recently described subtype characterized by a CpG island methylator phenotype (CIMP) has been associated with an especially poor prognosis. However, the drivers of CIMP remain unknown. Furthermore, the functional relation between CIMP and poor clinical outcomes of patients with adrenocortical carcinoma stays elusive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, we show that CIMP in adrenocortical carcinoma is linked to the increased expression of DNA methyltransferases <jats:italic>DNMT1<\/jats:italic> and <jats:italic>DNMT3A<\/jats:italic> driven by a gain of gene copy number and cell hyperproliferation. Importantly, we demonstrate that CIMP contributes to tumor aggressiveness by favoring tumor immune escape. This effect could be at least partially reversed by treatment with the demethylating agent 5-azacytidine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In sum, our findings suggest that co-treatment with demethylating agents might enhance the efficacy of immunotherapy and could represent a novel therapeutic approach for patients with high CIMP adrenocortical carcinoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-023-01534-5","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T02:01:22Z","timestamp":1690941682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Gwenneg","family":"Kerdivel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Amrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Calmejane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Carallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Hamroune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Assi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"1534_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","volume":"15","author":"J Crona","year":"2019","unstructured":"Crona J, Beuschlein F. Adrenocortical carcinoma\u2014towards genomics guided clinical care. Nat Rev Endocrinol. 2019;15:548\u201360.","journal-title":"Nat Rev Endocrinol"},{"key":"1534_CR2","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/jc.2005-2730","volume":"91","author":"G Abiven","year":"2006","unstructured":"Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1210\/jc.2005-2639","volume":"91","author":"B Allolio","year":"2006","unstructured":"Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"1534_CR4","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1210\/jc.2010-0803","volume":"95","author":"M Fassnacht","year":"2010","unstructured":"Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1534_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MED.0000000000000332","volume":"24","author":"J Varghese","year":"2017","unstructured":"Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017;24:208\u201314.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1534_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"1534_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assi\u00e9","year":"2014","unstructured":"Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607\u201312.","journal-title":"Nat Genet"},{"key":"1534_CR8","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","volume":"96","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa J-PJ. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci. 1999;96:8681\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"1534_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0065-230X(08)60702-2","volume":"72","author":"SB Baylin","year":"1998","unstructured":"Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141\u201396.","journal-title":"Adv Cancer Res"},{"key":"1534_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrc1507","volume":"4","author":"J-P Issa","year":"2004","unstructured":"Issa J-P. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988\u201393.","journal-title":"Nat Rev Cancer"},{"key":"1534_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbrc.2014.07.007","volume":"455","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014;455:35\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"1534_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/gad.294991.116","volume":"31","author":"NM Amankulor","year":"2017","unstructured":"Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774\u201386.","journal-title":"Genes Dev"},{"key":"1534_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730\u201349.","journal-title":"Cancer Discov"},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/0008-5472.CAN-17-3714","volume":"78","author":"S Luoto","year":"2018","unstructured":"Luoto S, Hermelo I, Vuorinen EM, Hannus P, Kesseli J, Nykter M, et al. Computational characterization of suppressive immune microenvironments in glioblastoma. Cancer Res. 2018;78:5574\u201385.","journal-title":"Cancer Res"},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunity. 2018;48:812-830.e14.","journal-title":"Immunity"},{"key":"1534_CR16","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","volume":"76","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76:1683\u20139.","journal-title":"Cancer Res"},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"E174","DOI":"10.1210\/jc.2012-2993","volume":"98","author":"O Barreau","year":"2012","unstructured":"Barreau O, Assi\u00e9 G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 2012;98:E174\u201384.","journal-title":"J Clin Endocrinol Metab"},{"key":"1534_CR18","doi-asserted-by":"crossref","unstructured":"Medvedeva YA, Lennartsson A, Ehsani R, Kulakovskiy IV, Vorontsov IE, Panahandeh P, et al. EpiFactors: a comprehensive database of human epigenetic factors and complexes. Database J Biol Databases Curation. 2015 [cited 2016 May 24];2015. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4494013\/","DOI":"10.1093\/database\/bav067"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/nar\/28.10.2108","volume":"28","author":"KD Robertson","year":"2000","unstructured":"Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)\/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 2000;28:2108\u201313.","journal-title":"Nucleic Acids Res"},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/cdd.2013.202","volume":"21","author":"D Pellacani","year":"2014","unstructured":"Pellacani D, Kestoras D, Droop AP, Frame FM, Berry PA, Lawrence MG, et al. DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death Differ. 2014;21:761\u201373.","journal-title":"Cell Death Differ"},{"key":"1534_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","volume":"168","author":"DH Spencer","year":"2017","unstructured":"Spencer DH, Russler-Germain DA, Ketkar-Kulkarni S, Helton NM, Lamprecht TL, Fulton RS, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168:801-816.e13.","journal-title":"Cell"},{"key":"1534_CR22","doi-asserted-by":"publisher","unstructured":"Martignetti L, Calzone L, Bonnet E, Barillot E, Zinovyev A. ROMA: Representation and quantification of module activity from target expression data. Front Genet. 2016 [cited 2017 Jan 30];7. https:\/\/doi.org\/10.3389\/fgene.2016.00018\/abstract","DOI":"10.3389\/fgene.2016.00018\/abstract"},{"key":"1534_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"1534_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.","journal-title":"Genome Biol"},{"key":"1534_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13\u201327.","journal-title":"Cancer Cell"},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","volume":"17","author":"H Noushmehr","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510\u201322.","journal-title":"Cancer Cell"},{"key":"1534_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0002-9440(10)63156-2","volume":"164","author":"T Etoh","year":"2004","unstructured":"Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164:689\u201399.","journal-title":"Am J Pathol"},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"6940","DOI":"10.18632\/oncotarget.14330","volume":"8","author":"DH Heiland","year":"2017","unstructured":"Heiland DH, Ferrarese R, Claus R, Dai F, Masilamani AP, Kling E, et al. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. Oncotarget. 2017;8:6940\u201354.","journal-title":"Oncotarget"},{"key":"1534_CR29","doi-asserted-by":"crossref","unstructured":"Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers. 2019 [cited 2020 Jul 10];11. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6966445\/","DOI":"10.3390\/cancers11122002"},{"key":"1534_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/gyno.1997.4667","volume":"65","author":"D Street","year":"1997","unstructured":"Street D, Kaufmann AM, Vaughan A, Fisher SG, Hunter M, Schreckenberger C, et al. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol. 1997;65:265\u201372.","journal-title":"Gynecol Oncol"},{"key":"1534_CR31","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","volume":"28","author":"M Martini","year":"2010","unstructured":"Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010;28:3548\u201357.","journal-title":"Vaccine"},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","volume":"25","author":"S Saghafinia","year":"2018","unstructured":"Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G. Pan-cancer landscape of aberrant DNA methylation across human tumors. Cell Rep. 2018;25:1066-1080.e8.","journal-title":"Cell Rep"},{"key":"1534_CR33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/carcin\/22.10.1615","volume":"22","author":"Y Nie","year":"2001","unstructured":"Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis. 2001;22:1615\u201323.","journal-title":"Carcinogenesis"},{"key":"1534_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ijc.11077","volume":"105","author":"E Fonsatti","year":"2003","unstructured":"Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer. 2003;105:430\u20131 (author reply 432-433).","journal-title":"Int J Cancer"},{"key":"1534_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxw025","volume":"28","author":"Y Takeuchi","year":"2016","unstructured":"Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401\u20139.","journal-title":"Int Immunol"},{"key":"1534_CR36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12272-017-0951-9","volume":"40","author":"HH Lee","year":"2017","unstructured":"Lee HH, Kang H, Cho H. Natural killer cells and tumor metastasis. Arch Pharm Res. 2017;40:1037\u201349.","journal-title":"Arch Pharm Res"},{"key":"1534_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/his.13674","volume":"73","author":"Y Kim","year":"2018","unstructured":"Kim Y, Wen X, Bae JM, Kim JH, Cho N-Y, Kang GH. The distribution of intratumoral macrophages correlates with molecular phenotypes and impacts prognosis in colorectal carcinoma. Histopathology. 2018;73:663\u201371.","journal-title":"Histopathology"},{"key":"1534_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00401-011-0904-1","volume":"123","author":"HA Rogers","year":"2012","unstructured":"Rogers HA, Kilday J-P, Mayne C, Ward J, Adamowicz-Brice M, Schwalbe EC, et al. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol (Berl). 2012;123:711\u201325.","journal-title":"Acta Neuropathol (Berl)"},{"key":"1534_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijc.29684","volume":"138","author":"B Gy\u0151rffy","year":"2016","unstructured":"Gy\u0151rffy B, Bottai G, Fleischer T, Munk\u00e1csy G, Budczies J, Paladini L, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer. 2016;138:87\u201397.","journal-title":"Int J Cancer"},{"key":"1534_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1399-0039.2009.01390.x","volume":"75","author":"Q Ye","year":"2010","unstructured":"Ye Q, Shen Y, Wang X, Yang J, Miao F, Shen C, et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2010;75:30\u20139.","journal-title":"Tissue Antigens"},{"key":"1534_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242263","volume":"15","author":"H Luo","year":"2020","unstructured":"Luo H, Ma C. Identification of prognostic genes in uveal melanoma microenvironment. PLoS ONE. 2020;15: e0242263.","journal-title":"PLoS ONE"},{"key":"1534_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s13046-019-1429-z","volume":"38","author":"K Saga","year":"2019","unstructured":"Saga K, Park J, Nimura K, Kawamura N, Ishibashi A, Nonomura N, et al. NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. J Exp Clin Cancer Res CR. 2019;38:416.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1534_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/carcin\/bgw032","volume":"37","author":"KD McCormick","year":"2016","unstructured":"McCormick KD, Ghosh A, Trivedi S, Wang L, Coyne CB, Ferris RL, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis. 2016;37:522\u20139.","journal-title":"Carcinogenesis"},{"key":"1534_CR44","doi-asserted-by":"publisher","first-page":"79292","DOI":"10.18632\/oncotarget.12685","volume":"7","author":"C Hantel","year":"2016","unstructured":"Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M, et al. Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget. 2016;7:79292\u2013304.","journal-title":"Oncotarget"},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.coemr.2019.08.009","volume":"8","author":"EM Pinto","year":"2019","unstructured":"Pinto EM, Kiseljak-Vassiliades K, Hantel C. Contemporary preclinical human models of adrenocortical carcinoma. Curr Opin Endocr Metab Res. 2019;8:139\u201344.","journal-title":"Curr Opin Endocr Metab Res"},{"key":"1534_CR46","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/cells11091439","volume":"11","author":"S Sigala","year":"2022","unstructured":"Sigala S, Bothou C, Penton D, Abate A, Peitzsch M, Cosentini D, et al. A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma. Cells. 2022;11:1439.","journal-title":"Cells"},{"key":"1534_CR47","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3390\/cancers13112660","volume":"13","author":"GJ Pegna","year":"2021","unstructured":"Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, et al. The immunotherapy landscape in adrenocortical cancer. Cancers. 2021;13:2660.","journal-title":"Cancers"},{"key":"1534_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00262-015-1776-3","volume":"65","author":"MH Saleh","year":"2016","unstructured":"Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother CII. 2016;65:787\u201396.","journal-title":"Cancer Immunol Immunother CII"},{"key":"1534_CR49","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","volume":"4","author":"J Wrangle","year":"2013","unstructured":"Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013;4:2067\u201379.","journal-title":"Oncotarget"},{"key":"1534_CR50","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1038\/s41388-018-0125-3","volume":"37","author":"Q Lai","year":"2018","unstructured":"Lai Q, Wang H, Li A, Xu Y, Tang L, Chen Q, et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN\/PD-L1 signal of lung cancer cells. Oncogene. 2018;37:2302\u201312.","journal-title":"Oncogene"},{"key":"1534_CR51","doi-asserted-by":"crossref","unstructured":"Fiorentini C, Grisanti S, Cosentini D, Abate A, Rossini E, Berruti A, et al. Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. J Oncol. 2019 [cited 2020 Jul 10];2019. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6463568\/","DOI":"10.1155\/2019\/6072863"},{"key":"1534_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7:253.","journal-title":"J Immunother Cancer"},{"key":"1534_CR53","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1210\/js.2019-00305","volume":"3","author":"L Head","year":"2019","unstructured":"Head L, Kiseljak-Vassiliades K, Clark TJ, Somerset H, King J, Raeburn C, et al. Response to immunotherapy in combination with mitotane in patients with metastatic adrenocortical cancer. J Endocr Soc. 2019;3:2295\u2013304.","journal-title":"J Endocr Soc"},{"key":"1534_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1101\/gad.255182.114","volume":"29","author":"MA Morgan","year":"2015","unstructured":"Morgan MA, Shilatifard A. Chromatin signatures of cancer. Genes Dev. 2015;29:238\u201349.","journal-title":"Genes Dev"},{"key":"1534_CR55","doi-asserted-by":"publisher","unstructured":"Gunz S, Kerdivel G, Meirer J, Shapiro I, Ragazzon B, Amrouche F, et al. The super-enhancer landscape reflects molecular subgroups of adrenocortical carcinoma. bioRxiv; 2023 [cited 2023 Apr 8]. p. 2023.04.05.535576. https:\/\/doi.org\/10.1101\/2023.04.05.535576v1","DOI":"10.1101\/2023.04.05.535576v1"},{"key":"1534_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1534_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.32614\/RJ-2016-047","volume":"8","author":"P Deveau","year":"2016","unstructured":"Deveau P, Barillot E, Boeva V, Zinovyev A, Bonnet E. Calculating biological module enrichment or depletion and visualizing data on large-scale molecular maps with ACSNMineR and RNaviCell packages. R J. 2016;8:293\u2013306.","journal-title":"R J"},{"key":"1534_CR58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ctm.ctm_69_16","volume":"3","author":"W Zhao","year":"2017","unstructured":"Zhao W, Li Y, Zhang X. Stemness-related markers in cancer. Cancer Transl Med. 2017;3:87\u201395.","journal-title":"Cancer Transl Med"},{"key":"1534_CR59","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen CL, Jensen JL, \u00d8rntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245\u201350.","journal-title":"Cancer Res"},{"key":"1534_CR60","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/bioinformatics\/btx154","volume":"33","author":"S Perrin","year":"2017","unstructured":"Perrin S, Firmo C, Lemoine S, Le Crom S, Jourdren L. Aozan: an automated post-sequencing data-processing pipeline. Bioinforma Oxf Engl. 2017;33:2212\u20133.","journal-title":"Bioinforma Oxf Engl"},{"key":"1534_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1534_CR62","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"1534_CR63","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.","journal-title":"Genome Biol"},{"key":"1534_CR64","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32:896\u2013902.","journal-title":"Nat Biotechnol"},{"key":"1534_CR65","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/1471-2164-14-774","volume":"14","author":"W Guo","year":"2013","unstructured":"Guo W, Fiziev P, Yan W, Cokus S, Sun X, Zhang MQ, et al. BS-Seeker2: a versatile aligning pipeline for bisulfite sequencing data. BMC Genomics. 2013;14:774.","journal-title":"BMC Genomics"},{"key":"1534_CR66","doi-asserted-by":"crossref","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012 [cited 2012 Mar 14]; http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22388286","DOI":"10.1038\/nmeth.1923"},{"key":"1534_CR67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bioinformatics\/btx595","volume":"34","author":"W Guo","year":"2018","unstructured":"Guo W, Zhu P, Pellegrini M, Zhang MQ, Wang X, Ni Z. CGmapTools improves the precision of heterozygous SNV calls and supports allele-specific methylation detection and visualization in bisulfite-sequencing data. Bioinforma Oxf Engl. 2018;34:381\u20137.","journal-title":"Bioinforma Oxf Engl"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01534-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:22:50Z","timestamp":1690946570000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01534-5","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Signed informed consent was obtained from all patients and the study was approved by the local institutional review board (Comit\u00e9 de protection des personnes Ile de France 1, application #13311).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"121"}}